178 related articles for article (PubMed ID: 33276986)
1. Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis.
Travaglino A; Raffone A; Gencarelli A; Saracinelli S; Riccardi C; Mollo A; Zullo F; Insabato L
Gynecol Oncol; 2021 Feb; 160(2):579-585. PubMed ID: 33276986
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas.
Zhang K; Liu Y; Liu X; Du J; Wang Y; Yang J; Li Y; Liu C
Pathology; 2021 Feb; 53(2):179-186. PubMed ID: 33070954
[TBL] [Abstract][Full Text] [Related]
3. Role of SMARCA4 (BRG1) and SMARCB1 (INI1) in Dedifferentiated Endometrial Carcinoma With Paradoxical Aberrant Expression of MMR in the Well-Differentiated Component: A Case Report and Review of the Literature.
Kaur R; Mehta J; Borges AM
Int J Surg Pathol; 2021 Aug; 29(5):571-577. PubMed ID: 32940101
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
[TBL] [Abstract][Full Text] [Related]
5. [Expression of SMARCA4(BRG1) and SMARCB1(INI1) in dedifferentiated and undifferentiated endometrial carcinomas and their correlations with clinicopathological features].
Bi R; Yu L; Tu XY; Ge HJ; Cheng YF; Chang B; Cai X; Jiang WH; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):590-595. PubMed ID: 31422588
[No Abstract] [Full Text] [Related]
6. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
7. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
8. Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.
Köbel M; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Stewart CJR; Lee CH
Am J Surg Pathol; 2018 Jan; 42(1):76-83. PubMed ID: 28863077
[TBL] [Abstract][Full Text] [Related]
9. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
[TBL] [Abstract][Full Text] [Related]
10. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
12. ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution.
Korentzelos D; Elishaev E; Zhao C; Jones MW; Soong TR; Lesnock J; Orellana T; Zeccola A; Diamantopoulos LN; Wald AI; Bhargava R
Hum Pathol; 2022 Dec; 130():65-78. PubMed ID: 36252860
[TBL] [Abstract][Full Text] [Related]
13. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
[TBL] [Abstract][Full Text] [Related]
15. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
17. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
18. SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma.
Stewart CJ; Crook ML
Pathology; 2015 Aug; 47(5):439-45. PubMed ID: 26126041
[TBL] [Abstract][Full Text] [Related]
19. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
Espinosa I; Lee CH; D'Angelo E; Palacios J; Prat J
Am J Surg Pathol; 2017 Aug; 41(8):1121-1128. PubMed ID: 28498284
[TBL] [Abstract][Full Text] [Related]
20. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]